Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.

Autor:	Araujo-Castro M; Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Madrid, Spain & Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain., Biagetti B; Department of Endocrinology and Nutrition, Hospital Universitario Vall de Hebrón, CIBERER U747 (ISCIII), ENDO-ERN, Barcelona, Spain., Menéndez Torre E; Department of Endocrinology and Nutrition, Hospital Universitario Central de Asturias & Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Asturias, Spain., Novoa-Testa I; Department of Endocrinology and Nutrition, Hospital Universitario de A Coruña, A Coruña, Spain., Cordido F; Department of Endocrinology and Nutrition, Hospital Universitario de A Coruña, A Coruña, Spain., Pascual-Corrales E; Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Madrid, Spain & Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain., Rodríguez Berrocal V; Department of Neurosurgery, Hospital Universitario Ramón y Cajal, Madrid, Spain., Guerrero-Pérez F; Department of Endocrinology and Nutrition, Hospital Universitario de Bellvitge, Cataluña L'Hospitalet de Llobregat, Spain., Vicente A; Department of Endocrinology and Nutrition, Hospital Universitario de Toledo, Toledo, Spain., Percovich Hualpa JC; Department of Endocrinology and Nutrition, Hospital Universitario Gregorio Marañón, Madrid, Spain., García-Centeno R; Department of Endocrinology and Nutrition, Hospital Universitario Gregorio Marañón, Madrid, Spain., González-Fernández L; Department of Endocrinology and Nutrition, Hospital Universitario Gregorio Marañón, Madrid, Spain., Ollero García MD; Department of Endocrinology and Nutrition, Hospital Universitario Navarra, Pamplona, Spain., Irigaray Echarri A; Department of Endocrinology and Nutrition, Hospital Universitario Navarra, Pamplona, Spain., Moure Rodríguez MD; Department Endocrinology and Nutrition, Hospital Universitario de Cruces, Bilbao, Spain., Novo-Rodríguez C; Department of Endocrinology and Nutrition, Hospital Universitario Virgen de las Nieves, Granada, Spain., Calatayud M; Department of Endocrinology and Nutrition, Hospital Universitario Doce de Octubre, Madrid, Spain., Villar-Taibo R; Department of Endocrinology and Nutrition, Hospital Universitario de Santiago de Compostela, Madrid, Spain., Bernabéu I; Department of Endocrinology and Nutrition, Hospital Universitario de Santiago de Compostela, Madrid, Spain., Alvarez-Escola C; Department of Endocrinology and Nutrition, Hospital Universitario La Paz, Madrid, Spain., Benítez Valderrama P; Department of Endocrinology and Nutrition, Hospital Universitario La Paz, Madrid, Spain., Tenorio-Jiménez C; Department of Endocrinology and Nutrition, Hospital Universitario Virgen de las Nieves, Granada, Spain., Abellán Galiana P; Department of Endocrinology and Nutrition, Hospital General Universitario de Castellón, Castellón, Spain.; Department of Medicine and Surgery, Universidad Cardenal Herrera-CEU, CEU Universities, Castellón, Spain., Venegas E; Department of Endocrinology and Nutrition, Hospital Universitario Virgen del Rocío, Sevilla, Spain., González-Molero I; Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, IBIMA Plataforma Bionand, Málaga, Spain., Iglesias P; Department of Endocrinology and Nutrition, Hospital Universitario Puerta de Hierro, Madrid, Spain., Blanco-Carrera C; Department of Endocrinology and Nutrition, Hospital Universitario Príncipe de Asturias, Madrid, Spain., Vidal-Ostos De Lara F; Department of Endocrinology and Nutrition, Hospital Universitario Príncipe de Asturias, Madrid, Spain., de Miguel Novoa P; Department of Endocrinology and Nutrition, Hospital Clínico San Carlos, Madrid, Spain., López Mezquita E; Department of Endocrinology and Nutrition, Hospital Universitario Clínico San Cecilio, Granada, Spain., Hanzu FA; Department of Endocrinology and Nutrition, Hospital Clinic de Barcelona, Barcelona, Spain., Aldecoa I; Biomedical Diagnostic Center, Department of Pathology, Hospital Clinic - University of Barcelona, Barcelona, Spain.; Neurological Tissue Bank of the Biobank, FCRB-IDIBAPS-Hospital Clinic Barcelona, Barcelona, Spain., Aznar S; Department of Endocrinology and Nutrition, Hospital Universitario De Albacete, Albacete, Spain., Lamas C; Department of Endocrinology and Nutrition, Hospital Universitario De Albacete, Albacete, Spain., Aulinas A; Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, IR-SANT PAU, CIBERER U747 (ISCIII), Barcelona, Spain.; Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain., Asla Q; Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, IR-SANT PAU, CIBERER U747 (ISCIII), Barcelona, Spain.; Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain., Gracia Gimeno P; Department of Endocrinology and Nutrition, Hospital Royo Villanova, Zaragoza, Spain., Recio-Córdova JM; Department of Endocrinology and Nutrition, Hospital Royo Villanova, Zaragoza, Spain., Avilés-Pérez MD; Department of Endocrinology and Nutrition, Hospital Universitario Clínico San Cecilio, Granada, Spain., Asensio-Wandosell D; Department of Endocrinology and Nutrition, Hospital Universitario Germans Trias i Pujol, Cataluña, Spain., Sampedro-Núñez M; Department of Endocrinology and Nutrition, Hospital Universitario La Princesa Madrid, Spain., Cámara R; Department of Endocrinology and Nutrition, Hospital Universitario y Politécnico La Fe, Valencia, Spain., Paja Fano M; Department of Endocrinology and Nutrition, OSI Bilbao-Basurto, Hospital Universitario de Basurto & University of the Basque Country UPV/EHU, Bilbao, Spain., Ruz-Caracuel I; Department of Pathology, Hospital Universitario Ramón y Cajal, IRYCIS & CIBER Cáncer (CIBERONC), Madrid, Spain., Fajardo C; Department of Endocrinology and Nutrition, Hospital Universitario La Ribera, Valencia, Spain., Marazuela M; Department of Endocrinology and Nutrition, Hospital Universitario La Princesa Madrid, Spain., Puig-Domingo M; Department of Endocrinology and Nutrition, Hospital Universitario Germans Trias i Pujol, Cataluña, Spain.
Jazyk:	angličtina
Zdroj:	Endocrine-related cancer [Endocr Relat Cancer] 2024 May 27; Vol. 31 (7). Date of Electronic Publication: 2024 May 27 (Print Publication: 2024).
DOI:	10.1530/ERC-24-0043
Abstrakt:	The objective of the study was to evaluate the efficacy of second-line therapies in patients with acromegaly caused by a growth hormone (GH) and prolactin (PRL) co-secreting pituitary neuroendocrine tumor (GH&PRL-Pit-NET) compared to their efficacy in patients with acromegaly caused by a GH-secreting pituitary neuroendocrine tumor (GH-Pit-NET). This is a multicenter retrospective study of patients with acromegaly on treatment with pasireotide and/or pegvisomant. Patients were classified in two groups: GH&PRL-Pit-NETs when evidence of hyperprolactinemia and immunohistochemistry (IHC) for GH and PRL was positive or if PRL were >200 ng/dL regardless of the PRL-IHC and GH-Pit-NETs when the previously mentioned criteria were not met. A total of 28 cases with GH&PRL-Pit-NETs and 122 with GH-Pit-NETs met the inclusion criteria. GH&PRL-Pit-NETs presented at a younger age, caused hypopituitarism, and were invasive more frequently than GH-Pit-NETs. There were 124 patients treated with pegvisomant and 49 with pasireotide at any time. The efficacy of pegvisomant for IGF-1 normalization was of 81.5% and of pasireotide of 71.4%. No differences in IGF-1 control with pasireotide and with pegvisomant were observed between GH&PRL-Pit-NETs and GH-Pit-NETs. All GH&PRL-Pit-NET cases treated with pasireotide (n = 6) and 82.6% (n = 19/23) of the cases treated with pegvisomant normalized PRL levels. No differences in the rate of IGF-1 control between pegvisomant and pasireotide were detected in patients with GH&PRL-Pit-NETs (84.9% vs 66.7%, P = 0.178). We conclude that despite the more aggressive behavior of GH&PRL-Pit-NETs than GH-Pit-NETs, no differences in the rate of IGF-1 control with pegvisomant and pasireotide were observed between both groups, and both drugs have shown to be effective treatments to control IGF-1 and PRL hypersecretion in these tumors.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu